Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes
Open Access
- 1 September 2002
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (9) , 3091-3093
- https://doi.org/10.1128/aac.46.9.3091-3093.2002
Abstract
The purpose of this study was to assess the effect of voriconazole on the blood tacrolimus concentration in a liver transplant recipient and to examine the interaction between voriconazole and tacrolimus by using human liver microsomes. Two subjects were enrolled in the clinical study: one received voriconazole, and the other received a placebo. Tacrolimus metabolism was evaluated in human liver microsomes at various concentrations in the absence and presence of various concentrations of voriconazole. Coadministration of voriconazole and tacrolimus resulted in elevated (nearly 10-fold-higher) trough tacrolimus blood concentrations in the liver transplant patient. In the in vitro study, voriconazole at a concentration of 10.4 ± 4.3 μg/ml inhibited the metabolism of tacrolimus by 50%. Clinically relevant concentrations of voriconazole inhibited the metabolism of tacrolimus in human liver microsomes. Close monitoring of the blood concentration and adjustment in the dose of tacrolimus are warranted in transplant recipients treated with voriconazole.Keywords
This publication has 14 references indexed in Scilit:
- Invasive Aspergillosis in Transplant RecipientsMedicine, 1999
- In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and VoriconazoleAntimicrobial Agents and Chemotherapy, 1998
- Update on Drug Interactions with Azole Antifungal AgentsAnnals of Pharmacotherapy, 1998
- Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida speciesAntimicrobial Agents and Chemotherapy, 1997
- Tacrolimus oral bioavailability doubles with coadministration of ketoconazole*Clinical Pharmacology & Therapeutics, 1997
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995
- The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*Clinical Pharmacology & Therapeutics, 1995
- Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes.1993
- Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.1992
- In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolismArchives of Biochemistry and Biophysics, 1992